<p>Cullen Frost Bankers Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 GSK PLC Sponsored ADR (NYSE:GSK - 免费报告) 的持股增加了 4.7%。该公司在此期间购买了额外的 16,999 股后，持有该制药公司 375,481 股股票。Cullen Frost Bankers Inc. 在 GSK 的持股在最近一个季度末价值为 14,418,000 美元。</p>
<ul>
<li>默克：购买此下跌的 4 个不容错过的理由</li>
</ul>
<p>其他机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度收购了 GSK 的新股份，价值约为 528,000 美元。GAMMA Investing LLC 在第一季度将其在 GSK 的股份增加了 107.8%。GAMMA Investing LLC 目前持有 4,447 股该制药公司的股票，价值 172,000 美元，此前在上个季度又收购了 2,307 股。Wealth Enhancement Advisory Services LLC 在第一季度将其在 GSK 的股份增加了 2.2%。Wealth Enhancement Advisory Services LLC 目前持有 178,510 股该制药公司的股票，价值 6,915,000 美元，此前在上个季度又收购了 3,822 股。Oppenheimer Asset Management Inc. 在第一季度将其在 GSK 的股份增加了 20.0%。Oppenheimer Asset Management Inc. 目前持有 140,106 股该制药公司的股票，价值 5,428,000 美元，此前在上个季度又收购了 23,369 股。最后，Aurora Private Wealth Inc. 在第一季度收购了 GSK 的新股份，价值约为 692,000 美元。15.74% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商最近对 GSK 发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 GSK 股票的 &#34;持有 (c)&#34; 评级。Wall Street Zen 在 9 月 5 日的研究报告中将 GSK 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。七位股票研究分析师对该股票给予了持有评级，一位分析师对该公司发布了卖出评级。根据 MarketBeat 的数据，GSK 目前的平均评级为 &#34;减持&#34;，平均目标价为 37.38 美元。</p>
<ul>
<li>在重置年后，Moderna 股票是否准备反弹？</li>
</ul>
<p><strong>查看我们关于 GSK 的最新报告</strong></p>
<h2>GSK 价格表现</h2>
<p>NYSE:GSK 周四开盘价为 44.21 美元。GSK PLC Sponsored ADR 的 52 周低点为 31.72 美元，52 周高点为 45.59 美元。该公司的速动比率为 0.57，流动比率为 0.87，债务与股本比率为 1.07。该公司的市值为 898.7 亿美元，市盈率为 20.47，市盈增长比率为 1.98，贝塔值为 0.53。该股票的 50 日移动平均线为 41.31 美元，200 日移动平均线为 39.16 美元。</p>
<ul>
<li>分析师预测 Wave Life Sciences 在降息后有 85% 的上涨空间</li>
</ul>
<p>GSK (NYSE:GSK - 获取免费报告) 最近在 7 月 30 日发布了季度财报。该制药公司报告每股收益为 1.23 美元，超出分析师一致预期的 1.12 美元，超出幅度为 0.11 美元。GSK 的股本回报率为 49.22%，净利润率为 10.81%。该公司在本季度的收入为 106.4 亿美元，而分析师预期为 79.2 亿美元。在去年同期，该公司每股收益为 0.43 美元。该公司的收入同比增长 1.3%。GSK 已将其 2025 财年的指引设定为每股收益 4.590-4.590。股票分析师预计 GSK PLC Sponsored ADR 本年度将发布每股收益 4.14 美元。</p>
<h2>GSK 减少股息</h2>
<p>该公司最近还宣布了季度股息，该股息于 10 月 9 日支付。8 月 15 日的登记投资者获得了每股 0.4206 美元的股息。这代表着年化股息为 1.68 美元，收益率为 3.8%。该股息的除息日期为 8 月 15 日。GSK 目前的派息比率为 78.24%。</p>
<h2>GSK 概况</h2>
<p>(免费报告)</p>
<p>GSK plc 及其子公司从事疫苗的研究、开发和生产，以及用于预防和治疗疾病的专科和普通药物，业务遍及英国、美国及国际市场。它通过两个部门运营，分别是商业运营和全面研发。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 GSK 更好</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>Archer 最近的一系列胜利标志着新的增长阶段</li>
<li>如何计算投资回报率 (ROI)</li>
<li>3 只关键股票在基本面改善中推动回购</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>选择股票的最佳 AI，按表现排名</li>
</ul>
<p><strong>想看看其他对冲基金持有 GSK 的情况吗？</strong> 访问 HoldingsChannel.com 获取 GSK PLC Sponsored ADR (NYSE:GSK - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GSK 吗？</h2>
<p>在考虑 GSK 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场关注之前购买……而 GSK 并不在名单上。</p>
<p>虽然 GSK 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GSK.WI

葛兰素史克

<p>Cullen Frost Bankers Inc. 在第二季度增加了对 GSK PLC Sponsored ADR 的持股，增幅为 4.7%，目前持有 375,481 股，价值 1440 万美元。其他机构投资者也调整了他们的持股。GSK 的股票在过去 52 周的价格区间为 31.72 美元至 45.59 美元，目前价格为 44.21 美元。该公司报告第二季度每股收益为 1.23 美元，超出预期，营收为 106.4 亿美元。GSK 最近宣布每股季度股息为 0.4206 美元，收益率为 3.8%</p>

<p>Cullen Frost Bankers Inc. raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375,481 shares of the pharmaceutical company's stock after purchasing an additional 16,999 shares during the period. Cullen Frost Bankers Inc.'s holdings in GSK were worth $14,418,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Cullen Frost Bankers Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 GSK PLC Sponsored ADR (NYSE:GSK - 免费报告) 的持股增加了 4.7%。该公司在此期间购买了额外的 16,999 股后，持有该制药公司 375,481 股股票。Cullen Frost Bankers Inc. 在 GSK 的持股在最近一个季度末价值为 14,418,000 美元。</p>
</div><ul>
<li>Merck: 4 No-Brainer Reasons to Buy This Dip</li>
</ul>
<div class="lb-trans"><ul>
<li>默克：购买此下跌的 4 个不容错过的理由</li>
</ul>
</div><p>Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of GSK in the fourth quarter worth approximately $528,000. GAMMA Investing LLC boosted its stake in shares of GSK by 107.8% in the first quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company's stock worth $172,000 after acquiring an additional 2,307 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of GSK by 2.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 178,510 shares of the pharmaceutical company's stock worth $6,915,000 after acquiring an additional 3,822 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of GSK by 20.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 140,106 shares of the pharmaceutical company's stock worth $5,428,000 after acquiring an additional 23,369 shares during the last quarter. Finally, Aurora Private Wealth Inc. acquired a new stake in shares of GSK in the first quarter worth approximately $692,000. 15.74% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度收购了 GSK 的新股份，价值约为 528,000 美元。GAMMA Investing LLC 在第一季度将其在 GSK 的股份增加了 107.8%。GAMMA Investing LLC 目前持有 4,447 股该制药公司的股票，价值 172,000 美元，此前在上个季度又收购了 2,307 股。Wealth Enhancement Advisory Services LLC 在第一季度将其在 GSK 的股份增加了 2.2%。Wealth Enhancement Advisory Services LLC 目前持有 178,510 股该制药公司的股票，价值 6,915,000 美元，此前在上个季度又收购了 3,822 股。Oppenheimer Asset Management Inc. 在第一季度将其在 GSK 的股份增加了 20.0%。Oppenheimer Asset Management Inc. 目前持有 140,106 股该制药公司的股票，价值 5,428,000 美元，此前在上个季度又收购了 23,369 股。最后，Aurora Private Wealth Inc. 在第一季度收购了 GSK 的新股份，价值约为 692,000 美元。15.74% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages recently commented on GSK. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of GSK in a research report on Wednesday, October 8th. Wall Street Zen upgraded GSK from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, September 5th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GSK presently has an average rating of &#34;Reduce&#34; and an average target price of $37.38.</p>
<div class="lb-trans"><p>多家券商最近对 GSK 发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 GSK 股票的 &#34;持有 (c)&#34; 评级。Wall Street Zen 在 9 月 5 日的研究报告中将 GSK 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。七位股票研究分析师对该股票给予了持有评级，一位分析师对该公司发布了卖出评级。根据 MarketBeat 的数据，GSK 目前的平均评级为 &#34;减持&#34;，平均目标价为 37.38 美元。</p>
</div><ul>
<li>After a Reset Year, Is Moderna Stock Poised for a Comeback?</li>
</ul>
<div class="lb-trans"><ul>
<li>在重置年后，Moderna 股票是否准备反弹？</li>
</ul>
</div><p><strong>View Our Latest Report on GSK</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GSK 的最新报告</strong></p>
</div><h2>GSK Price Performance</h2>
<div class="lb-trans"><h2>GSK 价格表现</h2>
</div><p>NYSE:GSK opened at $44.21 on Thursday. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $45.59. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $89.87 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.98 and a beta of 0.53. The stock's fifty day moving average is $41.31 and its two-hundred day moving average is $39.16.</p>
<div class="lb-trans"><p>NYSE:GSK 周四开盘价为 44.21 美元。GSK PLC Sponsored ADR 的 52 周低点为 31.72 美元，52 周高点为 45.59 美元。该公司的速动比率为 0.57，流动比率为 0.87，债务与股本比率为 1.07。该公司的市值为 898.7 亿美元，市盈率为 20.47，市盈增长比率为 1.98，贝塔值为 0.53。该股票的 50 日移动平均线为 41.31 美元，200 日移动平均线为 39.16 美元。</p>
</div><ul>
<li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师预测 Wave Life Sciences 在降息后有 85% 的上涨空间</li>
</ul>
</div><p>GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the previous year, the firm posted $0.43 earnings per share. The company's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.</p>
<div class="lb-trans"><p>GSK (NYSE:GSK - 获取免费报告) 最近在 7 月 30 日发布了季度财报。该制药公司报告每股收益为 1.23 美元，超出分析师一致预期的 1.12 美元，超出幅度为 0.11 美元。GSK 的股本回报率为 49.22%，净利润率为 10.81%。该公司在本季度的收入为 106.4 亿美元，而分析师预期为 79.2 亿美元。在去年同期，该公司每股收益为 0.43 美元。该公司的收入同比增长 1.3%。GSK 已将其 2025 财年的指引设定为每股收益 4.590-4.590。股票分析师预计 GSK PLC Sponsored ADR 本年度将发布每股收益 4.14 美元。</p>
</div><h2>GSK Cuts Dividend</h2>
<div class="lb-trans"><h2>GSK 减少股息</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Friday, August 15th. GSK's payout ratio is presently 78.24%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，该股息于 10 月 9 日支付。8 月 15 日的登记投资者获得了每股 0.4206 美元的股息。这代表着年化股息为 1.68 美元，收益率为 3.8%。该股息的除息日期为 8 月 15 日。GSK 目前的派息比率为 78.24%。</p>
</div><h2>GSK Profile</h2>
<div class="lb-trans"><h2>GSK 概况</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&amp;D.</p>
<div class="lb-trans"><p>GSK plc 及其子公司从事疫苗的研究、开发和生产，以及用于预防和治疗疾病的专科和普通药物，业务遍及英国、美国及国际市场。它通过两个部门运营，分别是商业运营和全面研发。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than GSK</li>
<li>What is MarketRank™? How to Use it</li>
<li>Archer’s Recent String of Victories Signals a New Phase of Growth</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>3 Key Stocks Boosting Buybacks Amid Improving Fundamentals</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 GSK 更好</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>Archer 最近的一系列胜利标志着新的增长阶段</li>
<li>如何计算投资回报率 (ROI)</li>
<li>3 只关键股票在基本面改善中推动回购</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>选择股票的最佳 AI，按表现排名</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GSK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 GSK 的情况吗？</strong> 访问 HoldingsChannel.com 获取 GSK PLC Sponsored ADR (NYSE:GSK - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=GSK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GSK Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GSK 吗？</h2>
</div><p>Before you consider GSK, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GSK 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场关注之前购买……而 GSK 并不在名单上。</p>
</div><p>While GSK currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GSK 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullen Frost Bankers Inc. 购入了 GSK PLC Sponsored ADR $GSK 的股份